About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Pembrolizumab for Advanced NSCLC and PS 2-3 | Clinical Trials | Clareo Health

RECRUITINGPhase 2

Pembrolizumab for Advanced NSCLC and PS 2-3

A Phase II Study of the Effects of Pembrolizumab on Quality of Life for Patients With Treatment-Naïve, Advanced or Metastatic NSCLC and Poor Performance Status

NCT05589818•Icahn School of Medicine at Mount Sinai

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Non-Small Cell Lung Cancer (NSCLC)

Interventions

Pembrolizumab

Locations

1

United States

Locations (1)

Mount Sinai Hospital

New York, New York, United States

Key Dates

Start Date

May 26, 2023

Primary Completion Date

May 1, 2027

Completion Date

May 1, 2028

Last Updated

June 25, 2025

Related Studies

RECRUITINGPhase 3

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

NCT07361497

Non-small Cell Lung Cancer (NSCLC)

Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab

NCT07510724

Small Cell Lung Cancer (SCLC)Non-Small Cell Lung Cancer (NSCLC)+1 more

RECRUITINGPhase 3

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

NCT06305754

Non-small Cell Lung Cancer (NSCLC)

RECRUITINGPhase 3

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

NCT05920356

Non-Small Cell Lung Cancer (NSCLC)

RECRUITINGPhase 1/2

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

NCT06128551

Non-Small Cell Lung Cancer (NSCLC)Colorectal Cancer+1 more

RECRUITINGPhase 3

Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer

NCT07251582

Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC)

View all related studies

Contacts

Deborah Doroshow, MD, PhD

CONTACT

212-241-5615 deborah.doroshow@mssm.edu

Bailey Fitzgerald, MD

CONTACT

Bailey.Fitzgerald@mountsinai.org

Sponsors

Lead Sponsor

Icahn School of Medicine at Mount Sinai

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 25, 2025Data synced to Clareo: April 27, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions